Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Downgrades Merck & Co to Neutral, Lowers Price Target to $76

UBS analyst Colin Bristow downgrades Merck & Co (NYSE:MRK) from Buy to Neutral and lowers the price target from $98 to $76.

December 13, 2021

1 minute read

UBS analyst Colin Bristow downgrades Merck & Co (NYSE:MRK) from Buy to Neutral and lowers the price target from $98 to $76.

Barclays Maintains Overweight on CSX, Raises Price Target to $38

Today, 6:19 AM

Barclays analyst Brandon Oglenski maintains CSX (NASDAQ:CSX) with a Overweight and raises the price target from $35 to $38.

Today, 6:19 AM

Ryder System, Inc. (NYSE:R) announces the opening of five new, used vehicle sales centers in Salt Lake City, Utah; Oklahoma City,…

Today, 6:19 AM

Mizuho analyst Vijay Rakesh maintains Applied Materials (NASDAQ:AMAT) with a Buy and lowers the price target from $180 to $160.

Today, 6:19 AM

Credit Suisse analyst Moshe Orenbuch maintains Visa (NYSE:V) with a Outperform and raises the price target from $235 to $245.